ArticleFrontiers in oncology2019

Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.

Lei Shang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.